Clinical Trial Update: Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating CC-1088 for myelodysplastic syndromes has completed, reporting safety and preliminary efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• CC-1088

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED